Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Staff of 1,000 Eyed for PMDA by FY2018: Parliamentary Secretary
November 6, 2013
- 93 MHLW Staff Members Received 2.95 Million Yen from Novartis Pharma from 3rd Quarter of 2008 through 1st Quarter of 2013
November 6, 2013
- Checking of Remaining Drugs Would Save 9.7 Billion Yen Annually: Estimate by Health and Labor Science Research Group
November 1, 2013
- New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium
October 31, 2013
- MHLW Investigating Whether Advertising for Diovan Violates PAL
October 31, 2013
- Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
- Causal Relationship between Tamiflu and Abnormal Behavior Not Identified: PAFSC Subcommittee
October 30, 2013
- Health Ministry Subcommittees Agree to Continue Suspending Recommendation for HPV Vaccines
October 30, 2013
- MHLW Discussing OTC Status for Certain In Vitro Diagnostics
October 30, 2013
- 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
- MHLW Rejects 2 Applicants for Cell-Based Flu Vaccine Subsidy Project
October 29, 2013
- Conclusion of TPP Talks over IP Rights Postponed
October 29, 2013
- Kenporen Calls for Taking 6 APIs Over the Counter
October 29, 2013
- LDP Establishes Study Group on Pharmaceutical Industry Policy; 11 Domestic Drug Makers to Participate
October 28, 2013
- TPP IP Talks Kick Off in Tokyo, Government Task Force to Hold Press Conference on Oct 28
October 25, 2013
- Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28
October 25, 2013
- Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member
October 24, 2013
- Lawmakers Concerned over Effects of Diovan Papers on Public Finances for Health Insurance
October 24, 2013
- Probable Price Settlement Rate of Lower 70% Range “Disappointing”: MHLW’s Economic Affairs Head Jo
October 24, 2013
- PFSB Notification Calls for Revisions to Precautions Sections of Package Inserts for Olmesartan and Other Drugs
October 24, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…